Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Main|Search|PHGKB
Search PHGKB:

Last Posted: Apr 21, 2024
spot light Highlights

Microbiome-based therapeutics

From the article: "The gut microbiome plays an important part in a number of gastrointestinal conditions, including Clostridioides difficile infection and inflammatory bowel disease. Interest in modulating the gut microbiome, through prebiotics, probiotics, and natural or artificial microbiota therapeutics, has increased markedly in the past decade. Although the field has developed rapidly, it has faced reproducibility issues and encountered safety and regulatory hurdles. This two-part Series explores the development and promise of artificial microbiome therapeutics, and the current and future perspectives for microbiota therapies for treating inflammatory bowel disease. "


Disclaimer: Articles listed in the Public Health Genomics and Precision Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.

TOP